Brittany’s cystic fibrosis birth incidence fell sharply, but the map became more uneven
Brittany has long carried one of France’s heaviest cystic fibrosis burdens, making it an unusually informative setting for tracking how genetics, reproductive counseling, newborn screening, and modern care reshape disease patterns over time. A regional registry spanning births from 1975 through 2024 captured 599 people with cystic fibrosis born in the region, allowing investigators to compare decades rather than isolated snapshots. The result is a rare fifty-year view of how incidence has changed in a population where the disease has always been common.
Birth incidence declined by 50.1% between the 1975-84 and 2015-24 decades, from 1 in 2,175 births to 1 in 4,361. The reduction was not gradual across the entire time window. A clear breakpoint emerged in the 1990s, pointing to a structural shift rather than random drift.
Prenatal diagnosis appears to have changed the trajectory
The timing of that breakpoint is clinically important because it coincides with the availability of prenatal diagnosis. In a hereditary disorder such as cystic fibrosis, once family planning options and prenatal testing become available, fewer affected pregnancies are expected to continue to delivery. That does not eliminate the underlying mutant allele pool, but it changes which pregnancies result in live birth and therefore alters birth incidence in a way that population registries can detect.
The data fit that biological and reproductive pattern. The decline accelerated after the 1990s, suggesting that diagnostic counseling and reproductive decision-making may have been as important to the fall in live-born cases as any change in the disease itself. Newborn screening, introduced in Brittany in 1989, also gave the region an early mechanism for case ascertainment, reducing the chance that later-year births would be missed. With both prenatal diagnosis and screening in place, the registry could track the disorder with unusual completeness across multiple generations.
A second shift ran through the geography of the disease.
Western Brittany carried a heavier burden than the east
The western-to-eastern gradient previously seen in Brittany did not disappear; it strengthened. During the most recent decade, 2015-24, western Brittany showed a birth incidence rate 84.9% higher than eastern Brittany, at 1 in 3,120 versus 1 in 5,769 births. The difference reached statistical significance with p = 0.035, and the pattern is consistent with the peninsula’s lower population mixing.
From a genetic epidemiology standpoint, reduced mixing can preserve founder effects and keep rare recessive disorders concentrated in specific areas. In cystic fibrosis, where carrier status may cluster within relatively stable local populations, marriage patterns, migration flows, and regional ancestry can all shape where affected births remain concentrated. The finding matters because it shows that a falling national or regional average can conceal pockets of persistently high risk. Public health planning built only on regional totals would miss that spatial concentration.
The study used Poisson regression to model these temporal and spatial trends, summarizing changes as average percent change between periods or departments. The statistical approach is appropriate for incidence counts over long intervals, especially when the question is not whether cystic fibrosis exists, but how its birth frequency moves across time and geography. In this case, the answer is mixed: overall decline, but widening internal disparity.
No early signal yet from highly effective CFTR modulators
The most recent clinical era is defined by elexacaftor/tezacaftor/ivacaftor, or ETI, the highly effective CFTR modulator regimen that has changed daily care for many people already living with cystic fibrosis. The study found no upward trend in birth incidence since expanded access to ETI in France. That matters because treatment gains in affected patients do not automatically translate into reduced incidence at birth. Modulator therapy improves function in diagnosed individuals; it does not directly remove carrier couples from the population or reverse inherited risk in conception.
There is also a practical reason to avoid overreading the short post-ETI interval. Shifts in incidence at birth often lag behind therapeutic revolutions because they are driven by reproductive behavior, prenatal testing, and population structure rather than by symptom control after diagnosis. If ETI influences family planning, carrier counseling, or reproductive decisions, those effects may take years to emerge in registry data. For now, the registry shows no detectable rise in live-born cases after access expanded.
Registry data give rare long-range clarity on a rare disease
Cystic fibrosis remains one of the most common rare genetic diseases, and Brittany’s registry offers a level of longitudinal detail that is hard to assemble elsewhere. Patients born before 1989 were identified by combining multiple data sources, while later births were captured through the newborn screening programme. That mixed ascertainment strategy is a strength, not a weakness, because it extends the observation window back to the 1970s while preserving more systematic capture in later years.
The study’s central message is straightforward. Over half a century, cystic fibrosis birth incidence in Brittany fell substantially, with the steepest inflection aligning with the era of prenatal diagnosis. The underlying burden did not vanish, and it did not distribute itself evenly across the region. Western Brittany remained more affected, and the gap widened rather than narrowed.
In clinical terms, the work reinforces two parallel responsibilities. Genetic counseling and reproductive services remain central to reducing new births with cystic fibrosis, and regional surveillance still matters because incidence can remain concentrated in geographic pockets even when the overall rate falls. Continued monitoring will be needed to determine whether the ETI era eventually leaves a measurable imprint on birth incidence or whether its impact stays confined to survival, lung function, and quality of life in those already born with the disease.